Labetuzumab

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]

Labetuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetcarcinoembryonic antigen
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.

This drug was developed by Immunomedics, Inc.

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab" (PDF). WHO Drug Information. 16 (1): 95. 2002.
  2. "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.